Scarica l'app Stockscreener
0.5623
2.24%
0.0123
Dopo l'orario di chiusura:
.55
-0.0123
-2.19%
Oragenics Inc Borsa (OGEN) Ultime notizie
0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - Yahoo! Finance Canada
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics Sets New 2025 Annual Shareholder Meeting Date - theglobeandmail.com
Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget
Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan
Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewswire
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
OGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Momentum Shift: Is Oragenics Inc vulnerable to short sellersJuly 2025 Update & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Oragenics Inc. stock trades pre earningsJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - mfd.ru
OGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
OGEN Should I Buy - Intellectia AI
Can Oragenics Inc. sustain its profitabilityJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Is Oragenics Inc. vulnerable to short sellers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
Oragenics previews targeted milestones for 2026 - Yahoo Finance
Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus
Oragenics Targets Projected $9 Billion Market by Advancing - GlobeNewswire
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - Yahoo Finance
Portfolio Shifts: What is the next catalyst for Oragenics IncJuly 2025 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Yahoo Finance
Oragenics (OGEN) Partners with Duck Flats Pharma for U.S. IND Re - GuruFocus
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - Sahm
Oragenics Advances Concussion Treatment Development with SCOPE Summit Participation Ahead of Australian Phase 2a Trial - citybuzz -
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care - GlobeNewswire
Investor Mood: Is Oragenics Inc stock technically oversold2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):